1 active not recruiting, 1 completed, 1 recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
Follow Metastatic Urethral Carcinoma: new trials by email Literature Review of Metastatic Urethral Carcinoma trials Research Report on Metastatic Urethral Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 314 | 2019-05-13 | 2026-10-26 |
| Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery Eribulin Mesylate, Gemcitabine Hydrochloride - Metastatic Ureter Carcinoma, Metastatic Urethral Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 26 | 2014-12-11 | 2019-12-16 |
Urethral Neoplasms (3) · Ureteral Neoplasms (2) · Urinary Bladder Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Lung Neoplasms (1) · Melanoma (1) · Penile Neoplasms (1) · Prostatic Neoplasms (1) · Urachal adenocarcinoma (1) · Urogenital Neoplasms (1)
Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Male Urogenital Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Urethral Diseases (3) · Urogenital Diseases (3) · Urologic Diseases (3) · Urologic Neoplasms (3) · Neoplasms by Histologic Type (2) · Ureteral Diseases (2) · Urinary Bladder Diseases (2) · Urogenital Neoplasms (2) · Adenocarcinoma (1) · Bronchial Neoplasms (1)
CTLA-4 Antigen (2) · Ipilimumab (2) · Nivolumab (2) · Disulfides (1) · Gemcitabine (1) · Immunoglobulin G (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · cabozantinib (1) · eribulin (1) · tocilizumab (1)
National Cancer Institute (NCI) (2) · M.D. Anderson Cancer Center (1)
United States (3) · Canada (1) · Puerto Rico (1)
Andrea B Apolo (1) · Rodabe Amaria, MD (1) · Sarmad Sadeghi (1)
PMID 31390274, PMID 35031545, PMID 35537412, PMID 37328287
N01CM00038 (1), P30CA093373 (1), U10CA180821 (1)